JP2017505800A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017505800A5 JP2017505800A5 JP2016551767A JP2016551767A JP2017505800A5 JP 2017505800 A5 JP2017505800 A5 JP 2017505800A5 JP 2016551767 A JP2016551767 A JP 2016551767A JP 2016551767 A JP2016551767 A JP 2016551767A JP 2017505800 A5 JP2017505800 A5 JP 2017505800A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic
- acid
- poly
- phase
- nanoparticle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002105 nanoparticle Substances 0.000 claims 75
- 230000001225 therapeutic effect Effects 0.000 claims 74
- 239000012071 phase Substances 0.000 claims 46
- 239000003814 drug Substances 0.000 claims 33
- 229940124597 therapeutic agent Drugs 0.000 claims 33
- 239000007864 aqueous solution Substances 0.000 claims 23
- 229920001223 polyethylene glycol Polymers 0.000 claims 23
- 238000010791 quenching Methods 0.000 claims 23
- 239000000839 emulsion Substances 0.000 claims 21
- 235000013336 milk Nutrition 0.000 claims 16
- 239000008267 milk Substances 0.000 claims 16
- 210000004080 milk Anatomy 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 16
- 238000004519 manufacturing process Methods 0.000 claims 15
- 239000002253 acid Substances 0.000 claims 14
- 238000000034 method Methods 0.000 claims 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 12
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 claims 11
- 230000000171 quenching effect Effects 0.000 claims 8
- 230000002209 hydrophobic effect Effects 0.000 claims 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 229920000858 Cyclodextrin Polymers 0.000 claims 5
- 239000012074 organic phase Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 238000004945 emulsification Methods 0.000 claims 4
- 230000001804 emulsifying effect Effects 0.000 claims 4
- 150000002500 ions Chemical class 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 239000008055 phosphate buffer solution Substances 0.000 claims 3
- 230000008685 targeting Effects 0.000 claims 3
- 239000001116 FEMA 4028 Substances 0.000 claims 2
- 229960004853 betadex Drugs 0.000 claims 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims 2
- 239000004327 boric acid Substances 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 2
- 230000005588 protonation Effects 0.000 claims 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 239000003840 Bafetinib Substances 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 1
- 206010014950 Eosinophilia Diseases 0.000 claims 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 claims 1
- 239000002137 L01XE24 - Ponatinib Substances 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims 1
- 150000001412 amines Chemical group 0.000 claims 1
- 229950002365 bafetinib Drugs 0.000 claims 1
- ZGBAJMQHJDFTQJ-DEOSSOPVSA-N bafetinib Chemical compound C1[C@@H](N(C)C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=NC=3)C(C)=CC=2)C=C1C(F)(F)F ZGBAJMQHJDFTQJ-DEOSSOPVSA-N 0.000 claims 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims 1
- 239000003613 bile acid Substances 0.000 claims 1
- 229960003736 bosutinib Drugs 0.000 claims 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 claims 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims 1
- 229960002448 dasatinib Drugs 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 125000000600 disaccharide group Chemical group 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 229960002411 imatinib Drugs 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 229960001346 nilotinib Drugs 0.000 claims 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000004214 philadelphia chromosome Anatomy 0.000 claims 1
- 229960001131 ponatinib Drugs 0.000 claims 1
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 229960001796 sunitinib Drugs 0.000 claims 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461939363P | 2014-02-13 | 2014-02-13 | |
| US61/939,363 | 2014-02-13 | ||
| PCT/US2015/015887 WO2015123562A1 (en) | 2014-02-13 | 2015-02-13 | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017505800A JP2017505800A (ja) | 2017-02-23 |
| JP2017505800A5 true JP2017505800A5 (enExample) | 2018-03-22 |
| JP6573895B2 JP6573895B2 (ja) | 2019-09-11 |
Family
ID=52595474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016551767A Active JP6573895B2 (ja) | 2014-02-13 | 2015-02-13 | 治療剤を含む治療用ナノ粒子ならびにその製造方法および使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10080723B2 (enExample) |
| EP (1) | EP3104838B1 (enExample) |
| JP (1) | JP6573895B2 (enExample) |
| CA (1) | CA2939261C (enExample) |
| DK (1) | DK3104838T3 (enExample) |
| ES (1) | ES2770733T3 (enExample) |
| HU (1) | HUE047934T2 (enExample) |
| PL (1) | PL3104838T3 (enExample) |
| PT (1) | PT3104838T (enExample) |
| SI (1) | SI3104838T1 (enExample) |
| WO (1) | WO2015123562A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3104838T3 (da) | 2014-02-13 | 2020-02-24 | Pfizer | Terapeutiske nanopartikler omfattende et terapeutisk middel og fremgangsmåder til fremstilling og anvendelse deraf |
| JP6554493B2 (ja) | 2014-06-24 | 2019-07-31 | ザ・トラスティーズ・オブ・プリンストン・ユニバーシティＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｐｒｉｎｃｅｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 可溶性生物製剤、治療薬およびイメージング剤をカプセル化するためのプロセス |
| EP3337516A4 (en) | 2015-08-21 | 2019-04-03 | Pfizer Inc | THERAPEUTIC NANOPARTICLES WITH A THERAPEUTIC PROCESS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| ES2797302T3 (es) * | 2016-03-22 | 2020-12-01 | Pfizer | Procedimiento para la preparación de nanopartículas terapéuticas |
| CA3060306A1 (en) * | 2017-05-09 | 2018-11-15 | Dignity Health | Drug delivery composition and method of fabrication |
| WO2019055539A1 (en) | 2017-09-12 | 2019-03-21 | Prudhomme Robert K | CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME |
| JP2021501753A (ja) * | 2017-11-03 | 2021-01-21 | ザ・トラスティーズ・オブ・プリンストン・ユニバーシティＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｐｒｉｎｃｅｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 徐放性ナノキャリア製剤を形成するための疎水性イオン対化およびフラッシュナノ沈殿 |
| CN112236459A (zh) * | 2018-04-23 | 2021-01-15 | 灰色视觉公司 | 改善的连续微粒制造 |
| EP3806858A4 (en) | 2018-06-15 | 2022-03-09 | Handa Pharmaceuticals, Inc. | KINA INHIBITOR SALTS AND COMPOSITIONS THEREOF |
| US12186436B2 (en) | 2018-07-19 | 2025-01-07 | The Trustees Of Princeton University | Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents |
| US11731099B2 (en) | 2018-07-20 | 2023-08-22 | The Trustees Of Princeton University | Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation |
| AU2023383352A1 (en) * | 2022-11-18 | 2025-06-05 | Haima Therapeutics, Llc | Lyophilization buffers for peptide-decorated liposomes |
| EP4658271A1 (en) | 2023-01-31 | 2025-12-10 | Handa Oncology, LLC | Improved cabozantinib compositions and methods of use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6869884B2 (en) * | 2002-08-22 | 2005-03-22 | Chartered Semiconductor Manufacturing Ltd. | Process to reduce substrate effects by forming channels under inductor devices and around analog blocks |
| BRPI0412211A (pt) * | 2003-07-23 | 2006-08-22 | Pr Pharmaceuticals Inc | composições de liberação controlada |
| JP2012501965A (ja) * | 2008-06-16 | 2012-01-26 | バインド バイオサイエンシズ インコーポレイテッド | 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法 |
| WO2014043625A1 (en) | 2012-09-17 | 2014-03-20 | Bind Therapeutics, Inc. | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
| US9877923B2 (en) | 2012-09-17 | 2018-01-30 | Pfizer Inc. | Process for preparing therapeutic nanoparticles |
| ES2784423T3 (es) * | 2013-09-16 | 2020-09-25 | Astrazeneca Ab | Nanopartículas poliméricas terapéuticas y métodos para su fabricación y uso |
| DK3104838T3 (da) | 2014-02-13 | 2020-02-24 | Pfizer | Terapeutiske nanopartikler omfattende et terapeutisk middel og fremgangsmåder til fremstilling og anvendelse deraf |
| MX378984B (es) * | 2014-03-14 | 2025-03-11 | Pfizer | Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso. |
-
2015
- 2015-02-13 DK DK15707019.4T patent/DK3104838T3/da active
- 2015-02-13 WO PCT/US2015/015887 patent/WO2015123562A1/en not_active Ceased
- 2015-02-13 SI SI201531085T patent/SI3104838T1/sl unknown
- 2015-02-13 EP EP15707019.4A patent/EP3104838B1/en active Active
- 2015-02-13 JP JP2016551767A patent/JP6573895B2/ja active Active
- 2015-02-13 US US15/118,737 patent/US10080723B2/en active Active
- 2015-02-13 ES ES15707019T patent/ES2770733T3/es active Active
- 2015-02-13 HU HUE15707019A patent/HUE047934T2/hu unknown
- 2015-02-13 PL PL15707019T patent/PL3104838T3/pl unknown
- 2015-02-13 PT PT157070194T patent/PT3104838T/pt unknown
- 2015-02-13 CA CA2939261A patent/CA2939261C/en active Active
-
2018
- 2018-09-07 US US16/124,605 patent/US10583092B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017505800A5 (enExample) | ||
| JP2015528510A5 (enExample) | ||
| Devulapally et al. | Polymer nanoparticles for drug and small silencing RNA delivery to treat cancers of different phenotypes | |
| Ardeshirzadeh et al. | Controlled release of doxorubicin from electrospun PEO/chitosan/graphene oxide nanocomposite nanofibrous scaffolds | |
| Naruphontjirakul et al. | Development of anti-HER2-targeted doxorubicin–core-shell chitosan nanoparticles for the treatment of human breast cancer | |
| HRP20191187T1 (hr) | Terapijske nanočestice koje sadrže terapijsko sredstvo, te postupci njihove proizvodnje i upotrebe | |
| Harrisson et al. | Nanoparticles with in vivo anticancer activity from polymer prodrug amphiphiles prepared by living radical polymerization | |
| EP2515946B1 (en) | Nanoconjugates and nanoconjugate formulations | |
| JP2017508803A5 (enExample) | ||
| JP2015520197A5 (enExample) | ||
| CA2922279C (en) | Therapeutic polymeric nanoparticles and methods of making and using same | |
| Limiti et al. | Hyaluronic acid–polyethyleneimine nanogels for controlled drug delivery in cancer treatment | |
| JP6573895B2 (ja) | 治療剤を含む治療用ナノ粒子ならびにその製造方法および使用方法 | |
| Ji et al. | Preparation, evaluation, and in vitro release of folic acid conjugated O‐carboxymethyl chitosan nanoparticles loaded with methotrexate | |
| RU2016149734A (ru) | Направленно доставляемые терапевтические наночастицы и способы их получения и использования | |
| JP2011519932A5 (enExample) | ||
| RU2018115566A (ru) | Терапевтические наночастицы, содержащие терапевтический агент, и их способы получения и применения | |
| Li et al. | A macromolecular prodrug strategy for combinatorial drug delivery | |
| CN107106496A (zh) | 高分子纳米粒子冷冻干燥物及其制备方法 | |
| Ramasamy et al. | Cationic drug-based self-assembled polyelectrolyte complex micelles: Physicochemical, pharmacokinetic, and anticancer activity analysis | |
| Albisa et al. | Polymeric nanomaterials as nanomembrane entities for biomolecule and drug delivery | |
| TW201625317A (zh) | 喜樹鹼類高分子衍生物之醫藥製劑 | |
| EP3119395B1 (en) | Polymeric nanoparticles and methods of making and using same | |
| KR101901649B1 (ko) | 서방형 하이드로겔 복합체의 제조방법 | |
| JP2018516964A5 (enExample) |